GAMMA Investing LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

GAMMA Investing LLC grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 804.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 67,474 shares of the company’s stock after purchasing an additional 60,016 shares during the quarter. GAMMA Investing LLC’s holdings in Teva Pharmaceutical Industries were worth $1,037,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $44,000. Versant Capital Management Inc increased its stake in Teva Pharmaceutical Industries by 437.8% in the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company’s stock valued at $81,000 after buying an additional 4,312 shares during the period. IFP Advisors Inc grew its stake in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC grew its stake in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock worth $96,000 after purchasing an additional 949 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 3.0%

NYSE:TEVA opened at $17.50 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The firm has a market capitalization of $20.07 billion, a price-to-earnings ratio of -12.07, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60. The stock has a fifty day simple moving average of $16.12 and a 200 day simple moving average of $17.43.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company posted $0.48 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now directly owns 9,989 shares of the company’s stock, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.49% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent research reports. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a “buy” rating and a $24.00 target price for the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Bank of America raised their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $24.44.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.